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Abstract. Gallic acid (GA), a polyphenol, is widely found 
in numerous fruits and vegetables, particularly in hickory 
nuts. In the present study, we found that gallic acid, a natural 
phenolic compound isolated from fruits and vegetables, had 
a more potent growth inhibitory effect on two ovarian cancer 
cell lines, OVCAR-3 and A2780/CP70, than the effect on a 
normal ovarian cell line, IOSE-364. These results demon-
strated that GA selectively inhibits the growth of cancer cells. 
Gene expression was examined by ELISA and western blot 
analysis, and gene pathways were examined by luciferase 
assay. It was found that GA inhibited VEGF secretion and 
suppressed in vitro angiogenesis in a concentration-dependent 
manner. GA downregulated AKT phosphorylation as well 
as HIF-1α expression but promoted PTEN expression. The 
luciferase assay results suggest that the PTEN/AKT/HIF-1α 
pathway accounts for the inhibitory effect of GA on VEGF 
expression and in vitro angiogenesis. These findings provide 
strong support for the high potential of GA in the prevention 
and therapy of ovarian cancer.
Introduction
Epidemiological studies have demonstrated that diets rich in 
fruits and vegetables have a chemopreventive effect on the 
development of cancer. It has been reported that phenolic 
compounds, a large family of natural compounds, abundant 
in fruits and vegetables, have been associated with a possible 
reduced risk of prostate cancer (1), breast cancer (2), liver 
cancer (3) and cervical cancer (4). The potential application of 
phenolic compounds in the development of therapeutic agents 
for cancer treatment and for their use as valuable additive 
or nutritional supplements to prevent cancer risk has gained 
increasing importance, and research in this field is currently 
expanding (5-7).
Ovarian cancer is one of the leading causes of cancer-
related mortality in women in developed areas (8). In 2015, an 
estimated 21,290 new cases and 14,180 deaths due to ovarian 
cancer occurred in the USA (9). Unfortunately, the overall 
survival rate at 5 years is only 50%, which has not significantly 
improved in the past 30 years (10). Even though the majority of 
women have successful initial therapy, the low rate of survival 
is due to eventual recurrence and succumbing to the disease. 
The treatment for ovarian cancer is still unsatisfactory, and 
new treatments for patients with recurrent ovarian cancer 
who are incurable with current management are needed. 
Another challenge is that more than 70% of women present 
with advanced stage disease (11). Symptoms of the disease 
generally do not present themselves until after the cancer has 
metastasized from the ovaries to the surfaces of the peritoneal 
cavity. Once metastasis has occurred, surgical removal of all 
lesions is no longer possible, making ovarian cancer extremely 
difficult to combat. The remaining first-line treatment option 
is chemotherapy.
Cytoreductive surgery followed by platinum and 
taxane-based combination chemotherapy is currently the stan-
dard treatment for ovarian cancer (12). Ovarian cancer is one 
of the most sensitive solid tumors, with objective responses 
ranging from 60 to 80% to chemotherapy even in patients with 
advanced stage disease. However, most patients ultimately 
recur and develop resistance to chemotherapy. Resistance 
to chemotherapy presents a major obstacle to improving the 
prognosis of patients with ovarian cancer. The response rate to 
current second-line or third-line (after interim non-platinum 
therapy) chemotherapy is <33% due to the rise in resistance 
to these drugs (13,14). Therefore, selecting new chemicals as 
cancer therapeutics from natural compounds is still crucial for 
ovarian cancer research. Finding new natural compounds that 
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match or exceed the effects of common chemical drugs, or are 
able to be given in combination with cisplatin to overcome 
resistance is of great significance (15). Our previous studies 
have shown that phenolic compounds are effective inhibitors 
of cell growth and vascular endothelial growth factor (VEGF) 
expression in ovarian cancer cells (16-18).
Gallic acid (3,4,5-trihydroxybenzoic acid, GA), a predomi-
nant polyphenol, is an endogenous plant polyphenol abundantly 
found in tea, grapes, berries and other fruits as well as in wine. 
GA has been shown to exhibit a variety of pharmacological 
and biological properties, including antibacterial, antiviral, 
and antitumor activities in many human cancer cell lines. Its 
anticancer activity has been reported in oral (19), lung (20), 
pancreatic (21), glioma (22) and cervical cancer cells (23).
In our previous experiments, we found that GA has the 
greatest inhibitory activity on human ovarian cancer cells 
among eight natural phenolic compounds from traditional 
Chinese medicine (24). However, the molecular mechanisms 
underlying the anti-angiogenic effects of GA on ovarian cancer 
have not been discussed in detail to date. In the present study, the 
inhibitory effect on cell proliferation, in vitro angiogenesis and 
VEGF expression by GA on human ovarian cancer cell lines 
was examined. In particular, the mechanism of GA-induced 
anti-angiogenesis in OVCAR-3 cells was further studied.
Materials and methods
Cell culture and treatment. Ovarian cancer cell line OVCAR-3 
was provided by Dr BingHua jiang of West Virginia University. 
IOSE-364, normal ovarian surface epithelial cells from healthy 
women, but immortalized with SV40 T/t, were courtesy of 
Dr Auersperg of the University of British Columbia, Canada. 
All cells were maintained in RPMI-1640 medium (Sigma) 
supplemented with 10% US-qualified fetal bovine serum 
(Invitrogen, Grand Island, NY, USA) in a cell culture incu-
bator with 5% CO2 at 37˚C. A stock solution of GA (Sigma) 
was prepared in dimethyl sulfoxide (DMSO) at 100 mM and 
stored at -20˚C. Different concentrations of GA were prepared 
in RPMI-1640 medium for cell treatments, and DMSO was 
included in the preparations to ensure equal concentrations of 
DMSO in each treatment.
Cell viability assay. To measure cell viability, cells were 
seeded in 96-well plates at a density of 1x104/well and allowed 
to recover, attach to the substrate, and grown to log phase over-
night. After incubation 37˚C, the culture medium was removed 
and incubated with different concentrations of GA for 24 h. 
Each treatment was performed in triplicate. After treatment, 
the cells were washed twice with phosphate-buffered saline 
(PBS), introduced to 100 µl freshly prepared AQueous One 
Solution (MTS tetrazolium compound) (Promega, Madison, 
WI, USA) in medium, and incubated for 1 h at 37˚C. The OD 
values, at 490 nm, were measured by an enzyme-linked immu-
nosorbent assay (ELISA) plate reader (Bio-Tek Instruments, 
Winooski, VT, USA). Cell viability was expressed as a 
percentage of the control.
VEGF protein quantification. The effect of GA on VEGF 
protein secretion was analyzed by ELISA with a Quantikine 
Human VEGF Immunoassay kit (R&D Systems, Minneapolis, 
MN, USA), targeting VEGF165 in the cell culture supernatant. 
Cells (6x105) were seeded in 60-mm cell culture dishes and 
allowed to attach to the substrate and grow for 16 h at 37˚C 
before treatment with various concentrations of GA for 24 h. 
Culture supernatants were collected for the VEGF assay. 
The inhibition of VEGF protein secretion was expressed as 
a percentage of the control. Cell lysates were also assayed for 
total protein levels using the BCA protein assay kit (Pierce, 
Rockford, IL, USA) to adjust VEGF levels.
In vitro angiogenesis assay. OVCAR-3 cancer cells were 
seeded in 60-mm cell culture dishes at 6x105 cells/dish and 
incubated overnight. Cells were then treated with 4 ml 
serum-free medium containing 0, 5, 10, or 20 µM GA for 
24 h and collected for the in vitro angiogenesis assay. Growth 
factor-reduced Matrigel (BD Biosciences, San jose, CA, USA) 
was transferred into 96-well plates at 50 µl/well and incubated 
at 37˚C for 1 h to gel. Human umbilical vein endothelial cells 
(HUVECs) were harvested in PBS, counted, and seeded 
onto the Matrigel beds at 2x104 cells/90 µl PBS. Thereafter, 
volumes of 10 µl of the collected conditioned media were 
added to each well. The system was incubated at 37˚C for 8 h, 
and tube formation was visualized under a microscope with 
images captured for comparison.
Western blot analysis. OVCAR-3 cancer cells were seeded and 
incubated overnight before treatment with GA. After a double 
wash with cold PBS, the cells were harvested with M-PER 
Mammalian Protein Extraction reagent supplemented with 
Halt protease and phosphatase inhibitor (both from Pierce), 
and total protein levels were assayed with the BCA protein 
assay kit. Cell lysates (50 µg total protein) were separated by 
SDS-PAGE and blotted onto a nitrocellulose membrane with 
a Mini-Protean 3 system (Bio-Rad, Hercules, CA, USA). For 
immunodetection, antibodies against HIF-1α, HIF-1β, AKT, 
p-AKT, PTEN and GAPDH (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) were applied, and signals were visualized 
with phycoerythrin-conjugated anti-mouse IgG secondary 
antibodies, SuperSignal West Pico Substrate, and X-ray film 
(Pierce). Protein bands were quantitated with NIH Imagej 
software and normalized by GAPDH bands for analysis.
Transient transfection and luciferase assay. OVCAR-3 cancer 
cells (1x104 cells/well) were seeded onto 96-well plates and 
incubated overnight. For transfection with hypoxia-inducible 
factor 1α (HIF-1α) plasmids (Addgene, Cambridge, MA, 
USA), cells were transfected with VEGF luciferase reporter 
(0.05 µg) and HIF-1α plasmids (0, 0.0625, 0.125 and 0.25 µg) 
or SR-a (as vehicle) plasmids using 0.6 µl of jetPRIME reagent 
(VWR, West Chester, PA, USA) for 4 h. For transfection with 
mAkt plasmids (Addgene), the cells were transfected with 
HIF-1α or VEGF luciferase reporter (0.05 µg) and mAkt (0, 
0.0625, and 0.125 µg) or the SR-a plasmids using 0.6 µl of 
jetPRIME reagent for 4 h. After transfection, all the cells 
were treated with or without GA (5 µM) for 16 h. The cells 
were harvested and analyzed for luciferase activity and total 
protein levels using a BCA protein assay kit, and the activities 
of VEGF reporter or the HIF-1α reporter were normalized to 
corresponding total protein levels for statistical analysis. The 
experiments were conducted 3-8 times.
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Statistical analysis. One-way ANOVA followed by Dunnett's 
test or by the Student's t-test was applied to compare the 
effects between chemical treatments. A p-value of <0.05 was 
considered as indicative of a statistically significant result.
Results and Discussion
GA inhibits cell proliferation and VEGF secretion 
dose‑dependently in an ovarian cancer cell line. Phenolic 
compounds, a large family of natural compounds with 
phenolic hydroxyls found in plants, fruits, vegetables and teas, 
have long been regarded as significant secondary metabolites 
for their chemopreventive and chemotherapeutic effects in 
cancer (25,26). In our previous experiments, eight natural 
phenolic compounds from traditional Chinese medicine were 
compared for their anti-proliferative effects on an ovarian 
cancer cell line at concentrations of 20 and 40 µM using a cell 
viability assay. We found that GA had the greatest inhibitory 
activity among these phenolic compounds (24). Therefore, GA 
was selected for subsequent experiments. Yet, we needed to 
clarify the appropriate dosage of GA needed to exert signifi-
cant effects and to determine the relative cytotoxic effects on 
ovarian cancer cell lines compared to normal ovarian cells. 
In the present study, we further examined the suppression 
of cell viability after treatment with varying concentrations 
of GA (0, 5, 10, 20 and 40 µM) in ovarian cancer cell lines 
(OVCAR-3, A2780/CP70) and in a normal ovarian cell line 
(ISOE-364).
As shown in Fig. 1, an overall inhibitory effect of GA on 
ovarian cancer cell lines and the normal ovarian cell line was 
tested. A2780/CP70 cell viability was significantly inhibited 
to 30.10% at 40 µM GA treatment. The inhibitory effect on 
OVCAR-3 cells was much higher than that on the A2780/CP70 
cells. OVCAR-3 cell viability was inhibited to 66.86 and 2.11% 
by 20 and 40 µM GA treatment, respectively. Compared to 
the inhibitory effect of cisplatin at 20 µM (16), the lower 
cell viabilities demonstrate that GA has high potential in the 
prevention and therapy of ovarian cancer.
Notably, GA did not have a significant inhibitory effect on 
the normal cell line (IOSE-364) at 40 µM. This result indicates 
that the inhibitory effects of GA on normal ovarian cells were 
less than that on the ovarian cancer cells. Therefore, GA selec-
tively inhibits cancer cells while having significantly weaker 
inhibitory effects on normal ovarian cells.
Many polyphenols have poor bioavailability, with about 
a 100-1,000 nM concentration in human serum. However, 
analyses of the bioavailability of polyphenols in humans 
reveal that GA performs better than other polyphenols (27). A 
concentration of ~8-10 µM of GA was detected in the serum 
of healthy volunteers, after oral intake of a combination of 
a dietary herbal supplement and 800 mg GA (28). The GA 
concentration found in this study is very close to therapeutic 
concentrations. A slight decrease in cell viability at 10 µM GA 
treatment was also observed, although this decrease did not 
reach statistical significance.
 VEGF is the best studied and the most potent pro-angiogenic 
factor known (29,30). For the purpose of angio-prevention, 
levels of VEGF were examined. As shown in Fig. 2A, VEGF 
expression in the A2780/CP70 cells and OVCAR-3 cells with 
40 µM GA treatment was significantly inhibited to 24.05 
Figure 1. Gallic acid (GA) inhibits cell proliferation in OVCAR-3 and 
A2780/CP70 ovarian cancer cells and ISOE 364 ovarian normal cells in a 
dose-dependent manner. Data represents means ± SE from 4 independent 
experiments. All data were analyzed by one-way ANOVA analysis followed 
by Dunnett's test. *P<0.05 as compared to the control; **P<0.01 as compared 
to the control.
Figure 2. The effect of gallic acid (GA) on VEGF expression and in vitro 
angiogenesis in ovarian cancer cell lines. (A) GA inhibited VEGF secre-
tion in OVCAR-3 and A2780/CP70 cells in a dose-dependent manner. The 
inhibitory effects on A2780/CP70 cells treated with 10 and 20 µM GA were 
different from the control but they were not significant (P=0.116 and 0.095, 
respectively). Data represents the means ± SE from three independent experi-
ments. All data were analyzed by one-way ANOVA analysis followed by 
Dunnett's test. *P<0.05 as compared to the control; **P<0.01 as compared to 
the control. (B) GA inhibits in vitro angiogenesis in OVCAR-3 cancer cells.
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and 27.12%, respectively. The inhibitory effect on OVCAR-3 
cells increased significantly when the concentrations were 
>5 µM while for A2780/CP70 cells the concentrations were 
>40 µM. Levels of VEGF excreted by OVCAR-3 cancer cells 
were inhibited to 82.75, 79.22, 68.88, and 27.12% by 5, 10, 20, 
and 40 µM GA treatments, respectively.
The inhibitory effect of GA on the OVCAR-3 cells was 
more pronounced than that on the A2780/CP70 cells. As 
shown in Fig. 2A, the inhibitory effects on A2780/CP70 cells 
treated with 10 and 20 µM GA were different from the control 
but they were not significant. This may be due to the lack of 
functional DNA mismatch repair of A2780/CP70 cells, which 
hampers the inhibitory effect of GA (31).
Since 8 to 10 µM of GA in the blood is attainable in humans 
following a plant-rich diet, our research suggests that GA can 
directly inhibit VEGF secretion of ovarian cancer cells at 
physiologically relevant concentrations. This is an exciting 
result which indicates that GA may have legitimate potential 
in treating cancer patients in the clinic.
GA inhibits in vitro angiogenesis induced by OVCAR‑3 in 
ovarian cancer cells. Angiogenesis, the formation of new 
blood vessels, is essential for tumor development and subse-
quent growth, invasion and metastasis. Suppressed expression 
of VEGF by kaempferol and chaetoglobosin K has been shown 
to inhibit in vitro angiogenesis in our previous research (17,32). 
GA may have a similar effect of inhibiting tube formation by 
HUVECs induced by VEGF. Therefore, we investigated the 
effect of GA on in vitro tube formation by HUVECs induced 
by the culture medium of ovarian cancer cells treated with 
different concentrations of GA. We found that the culture 
media conditioned by OVCAR-3 ovarian cancer cells promoted 
in vitro angiogenesis and presented a well-established network 
of HUVECs (Fig. 2B). Following treatment with increasing 
concentrations of GA treatment, the network was scattered 
down and HUVECs gradually lost their ability to form tube 
structures. A 20-µM GA treatment completely destroyed the 
network structure, and HUVECs were presented as mostly 
individual clumps. Similar to other compounds in our earlier 
research, GA inhibits in vitro angiogenesis through suppres-
sion of VEGF expression.
GA inhibits VEGF production through downregulation of 
HIF‑1α expression. It has been well established that hypoxia 
stimulates transcriptional activation of VEGF through induc-
tion of HIF-1α, and HIF-1α is considered a primary regulator 
of VEGF production. Thus, we first examined the influence 
of GA treatment on HIF-1α expression. It is generally thought 
that HIF-1α is regulated mainly by low oxygen or hypoxia as 
its name indicates. However, in concordance with our previous 
findings, HIF-1α is highly expressed in normoxic conditions 
in ovarian cancer cells (32). As expected, the protein levels 
of HIF-1α in the OVCAR-3 cancer cell line were markedly 
decreased with higher concentrations of GA. At 20 µM, the 
protein levels of HIF-1α were 23.48% of the levels of HIF-1β. 
This means that GA effectively decreased the protein expres-
sion of HIF-1α. These results suggest that HIF-1α may be 
involved in the inhibitory mechanism of VEGF production 
by GA treatment. To confirm that HIF-1α expression is not 
only regulated by GA treatment but also plays a role in the 
inhibition of VEGF secretion by GA, OVCAR-3 cells were 
transfected with the VEGF-promoter reporter, together with 
HIF-1α plasmids. As shown in Fig. 3B, this inhibition of VEGF 
was significantly reversed by forced expression of the HIF-1α 
protein. The higher the expression of HIF-1α, the higher the 
increase in the expression of the VEGF reporter. These results 
demonstrated that GA inhibits VEGF production through a 
HIF-1α-dependent pathway.
The transcription factor HIF-1 consists of two subunits, 
HIF-1α and HIF-1β. Research has shown that HIF-1β may be 
Figure 3. The effect of gallic acid (GA) on HIF-1α and HIF-1β protein expression in OVCAR-3 cells and luciferase assay after transfection with VEGF 
luciferase reporter and HIF-1α plasmids. (A) GA decreases HIF-1α protein expression. Data represents mean ± SE from 4 independent experiment. (B) HIF-1α 
mediates the inhibitory effect by GA on VEGF transcriptional activation. Data represents means ± SE from 6 independent experiments. **P<0.01 as compared 
to the control.
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regulated through an HIF-1α-dependent pathway (33). Thus, 
the protein levels of HIF-1β were also investigated. As shown 
in Fig. 3A, GA did not have a significant effect on the expres-
sion of HIF-1β. As generally regarded, HIF-1β is constitutively 
expressed in ovarian cancer cells. GA inhibits VEGF produc-
tion through transcription factor, HIF-1, by reducing the 
expression of HIF-1α.
GA inhibits HIF‑1α expression through blocking the phos‑
phorylation of AKT. It is commonly recognized that the 
PI3K pathway plays an important role in the regulation of 
cell growth, motility, survival and metabolism, as well as 
angiogenesis. AKT, identified as an oncogene in the 1980's, 
serves as a central sensor in the PI3K pathway and repre-
sents an attractive therapeutic target since multiple signaling 
components converge in AKT (34). To check whether the 
inhibition of the expression of HIF-1α and VEGF protein 
by GA is mediated by the AKT pathway, we first examined 
the levels of AKT and p-AKT protein after GA (0, 5, 10 and 
20 µM) treatment. As shown in Fig. 4A, the protein levels of 
p-AKT in the OVCAR-3 cancer cell line were decreased with 
higher concentrations of GA while no significant change in the 
protein levels of AKT was found. These results demonstrate 
that GA inhibits the phosphorylation of AKT. To show that 
the activation of AKT plays a role in the inhibition of HIF-1α 
and VEGF secretion by GA, OVCAR-3 cells were transfected 
with the HIF-1α promoter reporter, together with the mAKT 
plasmids. As shown in Fig. 4B and C, the inhibition of HIF-1α 
and VEGF was significantly reversed by forced expression of 
the mAKT protein, and the higher the expression of mAKT, 
the higher the expression of the HIF-1α reporter and VEGF 
reporter. These results demonstrate that GA inhibits HIF-1α 
and VEGF expression through blocking the phosphorylation 
of AKT. The regulating effect of AKT on HIF-1α or VEGF 
expression in ovarian cancer cells was also reported (35,36). 
Research into how the PI3K/AKT/mTOR pathway affects the 
progression and tumorigenesis of ovarian cancer may lead to 
new therapies that will increase the survival of these patients 
(37). The inhibitory effect of GA on the PI3K/Akt pathway 
demonstrates great therapeutic potential for ovarian cancer.
GA upregulates PTEN expression in OVCAR‑3 ovarian 
cancer cells. Phosphatase and tensin homolog deleted on 
Figure 4. The effect of gallic acid (GA) on p-AKT and AKT protein expres-
sion in OVCAR-3 cells and luciferase assay after transfection with mAKT 
plasmids and VEGF luciferase reporter or HIF-1α luciferase reporter. 
(A) GA decreases p-AKT protein expression in OVCAR-3 cells. Data rep-
resents mean ± SE from 5 independent experiment. (B) mAKT mediates the 
inhibitory effects of GA on VEGF expression in ovarian cancer cells. Data 
represents mean ± SE from 8 independent experiment. (C) mAKT mediates 
the inhibitory effects of GA on HIF-1α expression in ovarian cancer cells. 
Data represents mean ± SE from 4 independent experiments. *P<0.05 as 
compared to the control; **P<0.01 as compared to the control.
Figure 5. Gallic acid (GA) decreases p-AKT protein expression in OVCAR-3 
cells. Data represents mean ± SE from 5 independent experiments. *P<0.05 
as compared to the control.
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chromosome 10 (PTEN) is a tumor suppressor commonly 
mutated in many human cancers. PTEN hydrolyzes the 
3-phosphate on PIP3 to generate PIP2 and negatively regulates 
PIP3-mediated signaling pathways. AKT is one of the most 
important downstream targets of PI3K. Therefore, PTEN can 
control HIF-1α and VEGF expression through the PI3K/AKT 
pathway (38). To examine whether PTEN is involved in the 
inhibition of HIF-1α and VEGF expression by GA, the level 
of PTEN protein was investigated by western blot analysis. As 
shown in Fig. 5, the protein levels of PTEN in the OVCAR-3 
cancer cell line were increased following treatment with a 
high concentration of GA. This increase in PTEN protein 
expression indicates that GA may inhibit HIF-1α and VEGF 
expression through upregulating PTEN protein.
In conclusion, we investigated the molecular mechanism 
of GA concerning its inhibition of VEGF expression and 
in vitro angiogenesis activity. In the present study, GA was 
found to directly inhibit VEGF secretion of ovarian cancer 
cells at physiologically relevant concentrations (5 µM). These 
experiments demonstrate that GA has great potential in the 
prevention and therapy of ovarian cancer. To our knowledge, 
this is the first study that addresses the anti-angiogenesis effect 
of GA on ovarian cancer.
HIF-1, a transcription factor, can directly activate VEGF 
expression. Our research shows that GA inhibits VEGF 
production through the transcription factor, HIF-1 by mark-
edly reducing the expression of HIF-1α. GA can inhibit the 
expression of VEGF at low concentrations possibly due to the 
strong inhibition of the expression of HIF-1α. Furthermore, the 
inhibitory effect of GA may be involved in the suppression of 
AKT phosphorylation and upregulation of PTEN expression. 
A mechanism/pathway for the inhibition of VEGF expression 
by GA in ovarian cancer cells is proposed (Fig. 6). These find-
ings enhance our understanding of its mechanism of action 
and provide strong support for using this compound in future 
animal and clinical studies.
AKT is an important serine-threonine protein kinase and 
carries out various cellular functions such as angiogenesis, 
cell metabolism, cell survival/inhibition of apoptosis, and the 
cell cycle. The inhibition of AKT phosphorylation by GA may 
imply that GA induces various other cellular functions that 
require further study.
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